Abstract
Susceptibility to the biological consequences of aging varies among organs and individuals. We analyzed hepatocyte transcriptomes of healthy young and aged male mice to generate an aging hepatocyte gene signature, used it to deconvolute transcriptomic data from humans and mice with metabolic dysfunction-associated liver disease, validated findings with functional studies in mice and applied the signature to transcriptomic data from other organs to determine whether aging-sensitive degenerative mechanisms are conserved. We discovered that the signature enriches in diseased livers in parallel with degeneration. It is also enriched in failing human hearts, diseased kidneys and pancreatic islets from individuals with diabetes. The signature includes genes that control ferroptosis. Aged mice develop more hepatocyte ferroptosis and liver degeneration than young mice when fed diets that induce metabolic stress. Inhibiting ferroptosis shifts the liver transcriptome of old mice toward that of young mice and reverses aging-exacerbated liver damage, identifying ferroptosis as a tractable, conserved mechanism for aging-related tissue degeneration.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All data generated by the present study are included in this article and the Supplementary Information. The bulk RNA-seq data from the 6-week CDA-HFD-fed young versus old mice have been deposited in the GEO with accession no. GSE262457. The snRNA-seq data from the 22-week-old, chow- versus CDA-HFD-fed mice have also been submitted to the GEO and can be accessed with accession no. GSE262939. Additional public transcriptomic datasets for the samples discussed in the present study are available in the GEO database under the following accession nos.: GSE181761 (comparison of old versus young mouse HCs), GSE132042 (old versus young mouse liver), GSE213623 (Duke MASLD cohort), GSE33814 (German MASLD cohort), GSE167523 (Japanese MASLD cohort), GSE135251 (European MASLD cohort), GSE174748 (snRNA-seq on liver of controls and patients with MASLD) and GSE50244 (pancreatic islets). Moreover, the RNA-seq dataset for patients with heart failure was obtained from Zenodo at https://doi.org/10.5281/zenodo.4114616 (ref. 106). The RNA-seq dataset for patients with kidney fibrosis was sourced from E-MTAB-2502 on the EMBL-EBI website at https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-2502. In addition, the RNA-seq dataset for 226 healthy human livers was acquired from the GTEx Portal v.8 at https://gtexportal.org/home. Source data are provided with this paper.
Code availability
The present study did not generate any unique code or algorithm. The algorithms used for the analysis in the present study are all publicly available.
References
Chang, A. Y., Skirbekk, V. F., Tyrovolas, S., Kassebaum, N. J. & Dieleman, J. L. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. Lancet Public Health 4, e159–e167 (2019).
Sieck, G. C. Physiology in perspective: aging and underlying pathophysiology. Physiology 32, 7–8 (2017).
Tian, Y. E. et al. Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. Nat. Med. 29, 1221–1231 (2023).
Horvath, S. & Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat. Rev. Genet. 19, 371–384 (2018).
Maeso-Diaz, R. et al. Aging reduces liver resiliency by dysregulating Hedgehog signaling. Aging Cell 21, e13530 (2022).
Fitzgerald, K. N. et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging 13, 9419–9432 (2021).
Poganik, J. R. et al. Biological age is increased by stress and restored upon recovery. Cell Metab. 35, 807–820 e805 (2023).
Raj, K. & Horvath, S. Current perspectives on the cellular and molecular features of epigenetic ageing. Exp. Biol. Med. 245, 1532–1542 (2020).
Jensen-Cody, S. O. & Potthoff, M. J. Hepatokines and metabolism: deciphering communication from the liver. Mol. Metab. 44, 101138 (2021).
Rui, L. Energy metabolism in the liver. Compr. Physiol. 4, 177–197 (2014).
Timchenko, N. A. Aging and liver regeneration. Trends Endocrinol. Metab. 20, 171–176 (2009).
Kim, I. H., Kisseleva, T. & Brenner, D. A. Aging and liver disease. Curr. Opin. Gastroenterol. 31, 184–191 (2015).
Alqahtani, S. A. & Schattenberg, J. M. NAFLD in the elderly. Clin. Interv. Aging 16, 1633–1649 (2021).
Loomba, R. et al. DNA methylation signatures reflect aging in patients with non-alcoholic steatohepatitis. JCI Insight https://doi.org/10.1172/jci.insight.96685 (2018).
Palmer, A. K. & Jensen, M. D. Metabolic changes in aging humans: current evidence and therapeutic strategies. J. Clin. Invest. https://doi.org/10.1172/JCI158451 (2022).
Chen, T. et al. Hepatocyte smoothened activity controls susceptibility to insulin resistance and non-alcoholic fatty liver disease. Cell. Mol. Gastroenterol. Hepatol. 15, 949–970 (2023).
Maeso-Diaz, R. et al. Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression. Hepatology 78, 1209–1222 (2023).
Tam, B. T., Morais, J. A. & Santosa, S. Obesity and ageing: two sides of the same coin. Obes. Rev. 21, e12991 (2020).
Fabbrini, E., Sullivan, S. & Klein, S. Obesity and non-alcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679–689 (2010).
Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).
Carithers, L. J. et al. A novel approach to high-quality postmortem tissue procurement: the GTEx Project. Biopreserv. Biobank 13, 311–319 (2015).
Lonardo, A. et al. Sex differences in non-alcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 70, 1457–1469 (2019).
Filliol, A. et al. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature 610, 356–365 (2022).
Du, K. et al. Increased glutaminolysis marks active scarring in non-alcoholic steatohepatitis progression. Cell. Mol. Gastroenterol. Hepatol. 10, 1–21 (2020).
Stockwell, B. R. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401–2421 (2022).
Miao, R. et al. Iron metabolism and ferroptosis in type 2 diabetes mellitus and complications: mechanisms and therapeutic opportunities. Cell Death Dis. 14, 186 (2023).
Zhang, S. et al. Ferroptosis increases obesity: crosstalk between adipocytes and the neuroimmune system. Front. Immunol. 13, 1049936 (2022).
Zhang, H., Zhang, E. & Hu, H. Role of ferroptosis in non-alcoholic fatty liver disease and its implications for therapeutic strategies. Biomedicines https://doi.org/10.3390/biomedicines9111660 (2021).
Zheng, J. & Conrad, M. The metabolic underpinnings of ferroptosis. Cell Metab. 32, 920–937 (2020).
Duan, J. Y. et al. Ferroptosis and its potential role in metabolic diseases: a curse or revitalization? Front. Cell Dev. Biol. 9, 701788 (2021).
George, D. K. et al. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114, 311–318 (1998).
Sumida, Y. et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. J. Hepatol. 38, 32–38 (2003).
Nelson, J. E. et al. Relationship between the pattern of hepatic iron deposition and histological severity in non-alcoholic fatty liver disease. Hepatology 53, 448–457 (2011).
Buzzetti, E. et al. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. Liver Int. 39, 1325–1334 (2019).
Eder, S. K. et al. Mesenchymal iron deposition is associated with adverse long-term outcome in non-alcoholic fatty liver disease. Liver Int. 40, 1872–1882 (2020).
Nemeth, E. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090–2093 (2004).
Maus, M. et al. Iron accumulation drives fibrosis, senescence and the senescence-associated secretory phenotype. Nat. Metab. 5, 2111–2130 (2023).
Ferrucci, L. & Kuchel, G. A. Heterogeneity of aging: individual risk factors, mechanisms, patient priorities, and outcomes. J. Am. Geriatr. Soc. 69, 610–612 (2021).
Masaldan, S. et al. Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. Redox Biol. 14, 100–115 (2018).
Pirpamer, L. et al. Determinants of iron accumulation in the normal aging brain. Neurobiol. Aging 43, 149–155 (2016).
Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266–282 (2021).
Hardy, T., Oakley, F., Anstee, Q. M. & Day, C. P. Non-alcoholic fatty liver disease: pathogenesis and disease spectrum. Annu. Rev. Pathol. 11, 451–496 (2016).
Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging: an expanding universe. Cell 186, 243–278 (2023).
Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223–238 (2021).
Yu, D. et al. Higher dietary choline intake is associated with lower risk of non-alcoholic fatty liver in normal-weight Chinese women. J. Nutr. 144, 2034–2040 (2014).
Chai, C. et al. Dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2017–2018. Eur. J. Clin. Nutr. 77, 1160–1166 (2023).
He, S. & Sharpless, N. E. Senescence in health and disease. Cell 169, 1000–1011 (2017).
Coradduzza, D. et al. Ferroptosis and senescence: a systematic review. Int. J. Mol. Sci. https://doi.org/10.3390/ijms24043658 (2023).
Papatheodoridi, A. M., Chrysavgis, L., Koutsilieris, M. & Chatzigeorgiou, A. The role of senescence in the development of non-alcoholic fatty liver disease and progression to non-alcoholic steatohepatitis. Hepatology 71, 363–374 (2020).
Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat. Commun. 13, 4827 (2022).
Xiong, H. et al. Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron-induced hepatotoxicity. Hepatology 76, 387–403 (2022).
Tschuck, J. et al. Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis. Nat. Commun. 14, 6908 (2023).
Kim, D. H. et al. Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes. Redox Biol. 54, 102382 (2022).
Tang, J. et al. Farnesoid X receptor plays a key role in ochratoxin A-induced nephrotoxicity by targeting ferroptosis in vivo and in vitro. J. Agric. Food Chem. 71, 14365–14378 (2023).
Chiang, J. Y. L. & Ferrell, J. M. Bile acid metabolism in liver pathobiology. Gene Expr. 18, 71–87 (2018).
Wang, C. Y. & Babitt, J. L. Liver iron sensing and body iron homeostasis. Blood 133, 18–29 (2019).
Sanyal, A. J. et al. Prospective study of outcomes in adults with non-alcoholic fatty liver disease. N. Engl. J. Med. 385, 1559–1569 (2021).
Pei, Z. et al. FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis. Metabolism 122, 154840 (2021).
Zhao, X. et al. Adipose tissue macrophage-derived exosomes induce ferroptosis via glutathione synthesis inhibition by targeting SLC7A11 in obesity-induced cardiac injury. Free Radic. Biol. Med. 182, 232–245 (2022).
Balzer, M. S. et al. Single-cell analysis highlights differences in druggable pathways underlying adaptive or fibrotic kidney regeneration. Nat. Commun. 13, 4018 (2022).
Targher, G., Corey, K. E., Byrne, C. D. & Roden, M. The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol. 18, 599–612 (2021).
Elumalai, S., Karunakaran, U., Moon, J. S. & Won, K. C. Ferroptosis signaling in pancreatic beta-cells: novel insights & therapeutic targeting. Int. J. Mol. Sci. https://doi.org/10.3390/ijms232213679 (2022).
Vitalakumar, D., Sharma, A. & Flora, S. J. S. Ferroptosis: a potential therapeutic target for neurodegenerative diseases. J. Biochem. Mol. Toxicol. 35, e22830 (2021).
Hahn, V. S. et al. Myocardial gene expression signatures in human heart failure with preserved ejection fraction. Circulation 143, 120–134 (2021).
Salah, H. M. et al. Relationship of non-alcoholic fatty liver disease and heart failure with preserved ejection fraction. JACC Basic Transl. Sci. 6, 918–932 (2021).
Kang, H. M. et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21, 37–46 (2015).
Fadista, J. et al. Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proc. Natl Acad. Sci. USA 111, 13924–13929 (2014).
Bugianesi, E., McCullough, A. J. & Marchesini, G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42, 987–1000 (2005).
Rowe, J. W., Minaker, K. L., Pallotta, J. A. & Flier, J. S. Characterization of the insulin resistance of aging. J. Clin. Invest. 71, 1581–1587 (1983).
Miotto, G. et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 28, 101328 (2020).
Semmler, G., Datz, C., Reiberger, T. & Trauner, M. Diet and exercise in NAFLD/NASH: beyond the obvious. Liver Int. 41, 2249–2268 (2021).
Shu, Y. Y. et al. Attenuation by time-restricted feeding of high-fat and high-fructose diet-Induced NASH in mice is related to Per2 and ferroptosis. Oxid. Med. Cell Longev. 2022, 8063897 (2022).
Liu, T. et al. Treadmill training reduces cerebral ischemia-reperfusion injury by inhibiting ferroptosis through activation of SLC7A11/GPX4. Oxid. Med. Cell Longev. 2022, 8693664 (2022).
Violi, F. & Cangemi, R. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N. Engl. J. Med. 363, 1185–1186 (2010).
Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91–98 (2017).
Sumida, Y. & Yoneda, M. Current and future pharmacological therapies for NAFLD/NASH. J. Gastroenterol. 53, 362–376 (2018).
Han, J. X. et al. SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis. Acta Pharmacol. Sin. 44, 1161–1174 (2023).
Gu, Y. et al. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with non-alcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. Expert Rev. Gastroenterol. Hepatol. 17, 273–282 (2023).
An, J. R. et al. Liraglutide alleviates cognitive deficit in db/db mice: involvement in oxidative stress, iron overload, and ferroptosis. Neurochem. Res. 47, 279–294 (2022).
Li, Q. et al. Ferroptosis: the potential target in heart failure with preserved ejection fraction. Cells https://doi.org/10.3390/cells11182842 (2022).
Zhou, Y. et al. The role of ferroptosis in the development of acute and chronic kidney diseases. J. Cell. Physiol. 237, 4412–4427 (2022).
Wang, T. W. et al. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes. Nature 611, 358–364 (2022).
Luukkonen, P. K. et al. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in non-alcoholic steatohepatitis. Proc. Natl Acad. Sci. USA 120, e2217543120 (2023).
Lee, C. et al. Formyl peptide receptor 2 determines sex-specific differences in the progression of non-alcoholic fatty liver disease and steatohepatitis. Nat. Commun. 13, 578 (2022).
Fujinuma, S. et al. FOXK1 promotes non-alcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation. Cell Rep. 42, 112530 (2023).
Wang, Y. G. et al. Ferrostatin-1 inhibits toll-like receptor 4/NF-kappaB signaling to alleviate intervertebral disc degeneration in rats. Am. J. Pathol. 193, 430–441 (2023).
Chen, K. N. et al. Ferrostatin-1 obviates seizures and associated cognitive deficits in ferric chloride-induced posttraumatic epilepsy via suppressing ferroptosis. Free Radic. Biol. Med. 179, 109–118 (2022).
Xiao, Z. et al. Ferrostatin-1 alleviates lipopolysaccharide-induced cardiac dysfunction. Bioengineered 12, 9367–9376 (2021).
Wang, H. et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology 66, 449–465 (2017).
Yu, Y. et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. Blood 136, 726–739 (2020).
Yamada, N. et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: potential role of ferroptosis. Am. J. Transplant. 20, 1606–1618 (2020).
Jiang, H. et al. Ferrostatin-1 ameliorates liver dysfunction via reducing iron in thioacetamide-induced acute liver injury in mice. Front. Pharmacol. 13, 869794 (2022).
Liu, C. Y. et al. Ferroptosis is involved in alcohol-induced cell death in vivo and in vitro. Biosci. Biotechnol. Biochem. 84, 1621–1628 (2020).
Liu, B., Yi, W., Mao, X., Yang, L. & Rao, C. Enoyl coenzyme A hydratase 1 alleviates non-alcoholic steatohepatitis in mice by suppressing hepatic ferroptosis. Am. J. Physiol. Endocrinol. Metab. 320, E925–E937 (2021).
Li, S. et al. Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice. Front. Pharmacol. 13, 1081553 (2022).
Luo, Y. et al. Protective effects of ferroptosis inhibition on high fat diet-induced liver and renal injury in mice. Int. J. Clin. Exp. Pathol. 13, 2041–2049 (2020).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 14, 7 (2013).
Starmann, J. et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS ONE 7, e46584 (2012).
Kozumi, K. et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology 74, 2452–2466 (2021).
Govaere, O. et al. Transcriptomic profiling across the non-alcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aba4448 (2020).
Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083–1086 (2017).
Tabula Muris, C. et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 562, 367–372 (2018).
Knutsdottir, H. baderzone/HFpEF_2020: Data update. Zenodo https://doi.org/10.5281/zenodo.4114616 (2020).
Acknowledgements
This work was supported by the 2021 AASLD Pinnacle Award to K.D. and NIH grants (nos. R01 AA010154, R01 DK077794 and R56 DK134334) and Sponsored Research Study Agreement (no. 337521) supported by Boehringer Ingelheim Pharmaceuticals, awarded to A.M.D. We thank the patients who donated liver tissue for analysis, M. Abdelmalek and C. Guy and the clinical staff and coordinators who created and maintain the Duke NAFLD Biorepository, S. Gregory and his team at Duke Molecular Physiology Institute for snRNA-seq of control and MASLD liver tissues, and S. Pullen and his team at Boehringer Ingelheim Pharmaceuticals and Z. Man (Duke Department of Neurology) for their assistance in the bioinformatics analysis.
Author information
Authors and Affiliations
Contributions
K.D., L.W. and A.M.D. conceived the experiments. K.D., L.W. and J.H.J. performed the experiments. K.D., L.W., J.H.J., R.K.D., R.M.D., S.H.O., D.C.K. and A.M.D. analyzed the data. K.D., L.W., J.H.J. and A.M.D. wrote the paper. K.D. and A.M.D. secured the funding for the study. All authors reviewed and approved the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Aging thanks Philippe Lefebvre and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Top 10 upregulated/downregulated KEGG pathways in old versus young mouse hepatocytes.
Red arrows point to the upregulated pathways of interest, and blue arrows point to the downregulated pathways of interest. p values in GSEA plot was calculated using permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method.
Extended Data Fig. 2 Identification and characterization of the aging hepatocyte gene signature (AHGS).
(A) Number of DEGs in each gene set after applying different adjusted p-value cutoffs (p = 0.05 or 0.01) and log2 fold changes (1 - 5) for DEGs. (B) Jaccard index, examining similarity of overlapping DEGs of primary hepatocytes from old vs young mice fed with chow diet, and liver tissues from old vs young mice fed with CDA-HFD diet, revealed that AHGS with p-value < 0.01 and Log2 FC > 3 resulted in the best gene set by showing a reduced gene number and higher Jaccard similarity. (C) GO:MF (Molecular Function) clustering of the AHGS. Gene Set Enrichment Analysis (GSEA) of AHGS further identified (D) upregulated GO:BP (GO Biological Process) pathways and (E) upregulated HPO (Human Phenotype Ontology) pathways. p values were calculated using: unpaired two-tailed t.test in A, B; permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method in C, D, E.
Extended Data Fig. 3 Age is a major risk factor of MASLD development.
(A) Re-analysis of the Duke MASLD cohort (GSE213623) revealed that the chronological age positively correlates with MASLD histological markers including hepatocyte ballooning, portal inflammation and fibrosis in MASLD patients (control n = 69; MASLD patients n = 299; ballooning score 0, n = 32, score 1, n = 118, score 2, n = 149; portal_inf score 0, n = 146, score 1, n = 142; fibrosis F0F1, n = 97; F2, n = 107; F3F4, n = 95). **p < 0.01; ***p < 0.001; ****p < 0.0001. (B, C) GSEA using KEGG revealed that genes related to longevity and its associated mechanisms (for example nicotinamide; FoxO signaling) are depleted (B), while genes related to programmed cell death (C) are highly enriched in the transcriptomics of MASLD patients. Red arrows point to the pathways of interest. (D) AHGS enrichment increases with chronological age in MASLD patients but not control subjects. (E) AHGS enrichment score with chronological age in RNA-seq data of 226 normal liver samples from GTEx v8 database (https://gtexportal.org/home/). p-values were calculated using Wilcoxon Rank Sum test. Boxplot shows the upper quantile (75%), median (50%) and lower quantile (25%) of overall data distribution (A, D, E). p values in A, D, E were calculated using Wilcoxon Rank Sum test; p values in GSEA plots in B and C were calculated using permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method.
Extended Data Fig. 4 Aging-associated mechanisms are altered during MASLD development.
GSEA of bulk liver RNA seq data from Duke MASLD patients (GSE213623) revealed that (A) genes related to longevity and its associated mechanisms (for example NAD metabolism, sirtuins) are depleted, (B) while genes related to senescence are highly enriched in the transcriptomics of MASLD patients. (C) AHGS was applied to deconvolute bulk liver RNA seq data (GSE135251, heathy control n = 13; MASH n = 12). AHGS is enriched in transcriptomes of MASH patients and distinguishes MASH patients from healthy controls. Boxplot shows the upper quantile (75%), median (50%) and lower quantile (25%) of overall data distribution. p-values were calculated using: permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method in A, B; Wilcoxon Rank Sum test in C.
Extended Data Fig. 5 snRNA-seq analysis and bulk RNA-seq GSEA of MASLD liver.
(A, C) Uniform manifold approximation and projection (UMAP) visualization of liver cells in single-nucleus RNA-seq dataset generated from two MASLD patients or two healthy controls (GSE174748) (A), or mice fed with CDA-HFD diet or chow diet for 22 weeks (C). (B, D) We focused our analysis on the clusters that are most enriched for hepatocyte markers and depleted for non-hepatocyte markers in both human (B) and mouse dataset (D). GSEA of bulk liver RNA-seq data from Duke MASLD patients (GSE213623) revealed that genes related to (E) apoptosis, (F) pyroptosis and (G) necroptosis are all enriched in the liver transcriptomics of MASLD patients. p values in GSEA plots were calculated using permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method.
Extended Data Fig. 6 Livers of MASLD patients exhibit ferroptotic stress.
(A) Duke MASLD cohort patients (GSE213623) with the same fibrosis stage were stratified into young (age ≤ 35), middle age (35 <age < 55) and old groups (age ≥ 55). Expression of ferroptotic-associated genes was compared among the different age groups (age 20-35, fibrosis F0F1, n = 2; F2, n = 9; F3F4, n = 4; age 36-55, fibrosis F0F1, n = 55; F2, n = 61; F3F4, n = 39; age 56-80, fibrosis F0F1, n = 19; F2, n = 37; F3F4, n = 52). Box plot showed the upper quantile (75%), median (50%) and lower quantile (25%) (A) of overall data distribution in MASLD patients with different fibrosis stages. (B) Expression of genes related to iron homeostasis and (C) ferroptotic stress was compared between MASLD patients versus controls (healthy n = 2; MASLD n = 2). The average expression of in each single cell was calculated by the AddModuleScore function of Seurat. Feature plot showed single cells on dimensional reduction plot, with cell color indicating their relative expression levels. Violin plot showed the maxima, upper quantile (75%), median (50%), lower quantile (25%) and minima of overall data distribution in the healthy and MASLD group. p-values were calculated using: Wilcoxon Rank Sum test in A; unpaired two-tailed t.test in B, C.
Extended Data Fig. 7 Ferroptotic stress, lipotoxicity, inflammation and collagen metabolism are increased in livers of old mice.
(A) MDA levels were measured by western blots in livers and primary hepatocytes from chow-fed young (3 months old, n = 4) and old (2 years old, n = 5 for liver lysates, n = 4 for hepatocyte lysates). Data are graphed as mean ± SEM. (B) A published dataset (GSE132042) was re-analyzed to compare the transcriptomes of very old mouse liver ( ≥ 24 months old, n = 7) to young mouse liver ( ≤ 3 months old, n = 12). AHGS was enriched in the transcriptome of liver of aged mice. Boxplot shows the upper quantile (75%), median (50%) and lower quantile (25%) of overall data distribution. GSEA analysis further revealed that the transcriptomes of aged mouse liver are enriched with genes associated with (C) hepatocyte aging, (D) lipid metabolism, (E) inflammation and (F) collagen activity. p-values were calculated using: unpaired two-tailed t.test in A; Wilcoxon Rank Sum test in B; permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method in C, D, E, F.
Extended Data Fig. 8 Ferrostatin-1 protects hepatocytes from aging-related ferroptotic stress and senescence during diet-induced MASH.
Young and old mice were fed with a chow diet or CDA-HFD diet for 6 weeks. Old mice were intraperitoneally injected with Fer1 or its vehicle every other day during the last 8 days of feeding. (A) Body weights and liver weights were measured on the day of sacrifice (young+veh, n = 9; old+veh, n = 6; old+Fer-1, n = 6). (B) Expression of ferroptosis-related proteins detected by western blotting. (C) Representative Tfrc staining and quantification of the positively-stained areas (young+veh, n = 9; old+veh, n = 6; old+Fer-1, n = 6). Scale bars = 100μm (D) Expression of senescent marker p21 detected by western blotting. (E) GSEA demonstrated that transcriptome of old mice treated with Fer1 is depleted with genes involved in response to oxidative stress and related mortality. Protein expression was quantified by densitomeric analyses of western blots. Data are graphed as mean ± SEM. #p < 0.05 versus young mice + veh; $p < 0.05 versus old mice + veh. p-values were calcualted using: one-way ANOVA in A, B, C, D; permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method in E.
Extended Data Fig. 9 GSEA of the DEGs that reversed by ferrostatin1 in aged mice.
(A) Venn diagram identified 520 DEGs that were upregulated in old mice (vs young mice + veh) but reversed by Fer1 (vs old mice + veh). GSEA further identified 14 significantly enriched hallmark pathways in these DEGs. (B) Venn diagram identified 658 DEGs that were downregulated in old mice (vs young mice + veh) but reversed by Fer1 (vs old mice + veh). GSEA further identified 7 significantly enriched hallmark pathways in these DEGs. p values were calculated using permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method.
Extended Data Fig. 10 FXR and ferroptotic stress interact to modulate age-dependent susceptibility to MASLD.
Young and old mice were fed with CDA-HFD diet for 6 weeks. These mice were intraperitoneally injected with Fer1 or its vehicle every other day during the last 8 days of feeding. Transcriptomes of liver tissues were analysed by RNA-seq (n = 4 mice/group). (A) GSEA demonstrated that liver transcriptome of old mice is depleted of genes involved in bile acid metabolism and this is reversed by Fer1 treatment in the old mice. (B) Expression of FXR/Nr1h4. (C) GSEA demonstrated that liver transcriptome of old mice is depleted of genes involved in FXR pathway activity, and this is reversed by Fer1 treatment in the old mcie. (D) Expression of FXR/Nr1h4 in liver of Duke NAFLD cohorts (GSE213623). (E) Expression of FXR/Nr1h4 in hepatocytes subpopulations from single-nucleus RNA-seq dataset of two MASLD patients or two healthy controls (GSE174748). The average expression of in each single cell was calculated by the AddModuleScore function of Seurat. Feature plot showed single cells on dimensional reduction plot, with cell color indicating their relative expression levels. Box plot showed the upper quantile (75%), median (50%) and lower quantile (25%) (B, D), while violin plot showed the maxima, upper quantile (75%), median (50%), lower quantile (25%) and minima (E) of overall data distribution. p-values were calcualted using: permutation test, then adjusted for multiple comparison testing using the Benjamini-Hochberg method in A, C; Wilcoxon Rank Sum test in B, D; unpaired two-tailed t.test in E.
Supplementary information
Supplementary Information
Supplementary Tables 2–5.
Supplementary Table 1
AHGS Aging_geneSig_l2fc.
Source data
Source Data Fig. 3
Statistical source data.
Source Data Fig. 4
Statistical source data.
Source Data Fig. 4
Unprocessed western blots.
Source Data Fig. 5
Statistical source data.
Source Data Fig. 6
Statistical source data.
Source Data Fig. 7
Statistical source data.
Source Data Fig. 7
Unprocessed western blots.
Source Data Extended Data Fig. 7
Statistical source data.
Source Data Extended Data Fig. 7
Unprocessed western blots.
Source Data Extended Data Fig. 8
Statistical source data.
Source Data Extended Data Fig. 8
Unprocessed western blots.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Du, K., Wang, L., Jun, J.H. et al. Aging promotes metabolic dysfunction-associated steatotic liver disease by inducing ferroptotic stress. Nat Aging (2024). https://doi.org/10.1038/s43587-024-00652-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s43587-024-00652-w